Bayer tees up $7.25B settlement to wrap Roundup cancer lawsuits
Bayer and plaintiffs’ lawyers unveiled a proposed nationwide settlement of up to $7.25 billion to resolve more than 125,000 U.S. Roundup cancer lawsuits, funded over as many as 21 years with payouts varying by exposure and age. The deal, which still needs Missouri court approval, would provide compensation even if the Supreme Court sides with Bayer on labeling preemption, while potentially shielding the company from larger future costs. Separately, Bayer has halted glyphosate in U.S. residential markets but continues its use in agriculture; regulators say glyphosate is unlikely to be carcinogenic when used as directed. Some plaintiffs’ attorneys say payouts are too small and opt-outs could derail the agreement.),
